MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
Previous PostMedinCell to take part in Jefferies Global Healthcare Conference - London, 14-16 November
Next PostParticipation terms in the Combined General Meeting
